Erschienen in:
09.08.2022 | Letter to the Editor
Cutaneous silent period in ATTRv carriers: a possible early marker of nerve damage?
verfasst von:
Marco Luigetti, Andrea Di Paolantonio, Valeria Guglielmino, Angela Romano
Erschienen in:
Neurological Sciences
|
Ausgabe 12/2022
Einloggen, um Zugang zu erhalten
Excerpt
Hereditary transthyretin amyloidosis (ATTRv,
v for “variant”) is an adult-onset, autosomal dominant, multisystemic disease caused by mutations in the gene encoding transthyretin (
TTR)[
1]. In the last few years, the ATTRv therapeutic scenario has dramatically changed thanks to the availability of new drugs potentially able to prevent or delay disease progression but maximally effective if started in the early stages [
1]. This raises the need for reliable disease biomarkers that might allow to early identify disease onset in pre-symptomatic TTR mutation carriers, thus permitting prompt treatment initiation as soon as minor, but clinically meaningful, disease signs are detected[
2]. …